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Reserpine is an irreversible inhibitor of vesicular monoamine transporter-2 (VMAT2) used
to study Parkinson’s disease (PD) and screening for antiparkinsonian treatments in
rodents. Recently, the repeated treatment with a low-dose of reserpine was proposed
as a progressive model of PD. Rats under this treatment show progressive catalepsy
behavior, oral movements and spontaneous motor activity decrement. In parallel,
compared to Wistar rats, spontaneously hypertensive rats (SHR) are resistant to acute
reserpine-induced oral dyskinesia. We aimed to assess whether SHR would present
differential susceptibility to repeated reserpine-induced deficits in the progressive model
of PD. Male Wistar and SHR rats were administered 15 subcutaneously (s.c.) injections
of reserpine (0.1 mg/kg) or vehicle, every other day and motor activity was assessed
by the catalepsy, oral movements and open field tests. Only reserpine-treated Wistar
rats presented increased latency to step down in the catalepsy test and impaired
spontaneous activity in the open field. On the other hand, there was an increase in
oral movements in both reserpine-treated strains, although with reduced magnitude and
latency to instauration in SHR. After a 15-day withdrawn period, both strains recovered
from motor impairment, but SHR animals expressed reduced latencies to reach control
levels. Finally, we performed immunohistochemistry for tyrosine hydroxylase (TH) and
α-synuclein (α-syn) 48 h after the last injection or 15 days after withdrawn. Reserpine-
treated animals presented a reduction in TH and an increase in α-syn immunoreactivity
in the substantia nigra and dorsal striatum (dSTR), which were both recovered after
15 days of withdraw. Furthermore, SHR rats were resistant to reserpine-induced TH
decrement in the substantia nigra, and presented reduced immunoreactivity to α-syn in
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the dSTR relative to Wistar rats, irrespective of treatment. This effect was accompanied
by increase of malondaldhyde (MDA) in the striatum of reserpine-treated Wistar rats,
while SHR presented reduced MDA in both control and reserpine conditions relative to
Wistar strain. In conclusion, the current results show that SHR are resilient to motor
and neurochemical impairments induced by the repeated low-dose reserpine protocol.
These findings indicate that the neurochemical, molecular and genetic differences in the
SHR strain are potential relevant targets to the study of susceptibility to PD.
Keywords: reserpine, Parkinson’s disease, SHR, α-synuclein, tyrosine hydroxylase
INTRODUCTION
Parkinson’s disease (PD) is the second most prevalent
neurodegenerative disease, estimated to affect 1%–2% of
those older than 60 years, and 7–10 million people worldwide
(Mayeux, 2003; Van Den Eeden et al., 2003). Most importantly, it
is a disorder with progressive onset and escalating deterioration
of life quality (Braak et al., 2003). Therefore, the resulting
social and economic burdens to countries with increasing life
expectancy justify a growing scientific effort to understand its
physiopathology.
The disease is characterized by motor impairments including
muscular weakness, rigidity, postural instability, tremors and
bradykinesia (Klockgether, 2004; Duty and Jenner, 2011).
However, non-motor alterations such as anxiety, depression,
anhedonia, deficit in executive function, dementia and sleep
disturbances are also present (Comella, 2003; Schneider et al.,
2003; Bowers et al., 2006; Ishihara and Brayne, 2006; Barone,
2011; Gómez-Esteban et al., 2011; Voon and Dalley, 2011).
The motor symptoms are the result of the progressive and
irreversible loss of dopaminergic neurons in the substantia
nigra pars compacta (SNpc). Such loss of dopaminergic inputs
concurrently progresses with the accumulation of intracellular
α-synuclein (α-syn)-rich protein inclusions, known as Lewy
bodies (McNaught et al., 2001; Lotharius and Brundin, 2002).
The scientific literature highlights a number of genes
associated to the inheritance of PD, such as α-syn, parkin,
PINK1, DJ-1 and LRRK. Nevertheless, familial forms of PD
explains only 10%–15% of the cases (Gao and Hong, 2011).
The majority of cases are reported as idiopathic or sporadic,
and are associated to environmental factors such as exposition
to pesticides, rural life, infection, head trauma, and emotional
disturbances like anxiety and depression (Godeiro et al., 2010;
Noyce et al., 2012). Nonetheless, these epidemiological findings
suggest that there are cumulative interactions between genetic
and environmental factors that lead to the disease (Kim et al.,
2005).
Despite many studies investigating the relevance of punctual
genetic mutations in neurotoxic PD animal models (von
Bohlen und Halbach et al., 2004; von Bohlen und Halbach,
2006), few of them investigated the differences between
strains upon the expression of the parkinsonian phenotype.
The use of distinct rodent strains could help to enlighten
mechanisms related to sensitivity to neurotoxic insults.
Specifically, physiological variations related to susceptibility
to a dopaminergic insult in different rat strains would be
relevant in the context of the multifactorial etiology of PD. For
example, a study associated the resistance to the dopaminergic
insult induced by the parkinsonian agent 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP) to autosomic alleles of
the C57BL/J6 mice strain (Hamre et al., 1999). Of notice,
spontaneously hypertensive rats (SHR) are resistant to the
high-dose reserpine-induced oral dyskinesia. Further, this
resistance is attributed to the increased activity of the antioxidant
enzyme catalase in the striatum exhibited by the SHR animals
(Queiroz et al., 1998; Abílio et al., 2004). Interestingly, studies
have shown that SHR present other neurochemical differences
compared to normotensive strains that could be related to
the pathophysiology of PD, such as variances in dopaminergic
systems (Viggiano et al., 2004) and decreased α-syn expression in
the hippocampus (Chiavegatto et al., 2009). However the effects
of parkinsonian-inducing agents on these parameters have not
been investigated in this strain yet.
Reserpine is a vesicular monoamine transporter-2 (VMAT2)
inhibitor extracted from Rauwolfia serpentina. This drug depletes
monoamines in the central nervous system and produces
lethargy, depression and dyskinesia (Leão et al., 2015). Due
to these properties, reserpine was employed to model the
motor and non-motor deficits related to PD in rodents
and screen for candidate pharmacological treatments to PD
(Jurna et al., 1973; Goldstein et al., 1975; Ossowska et al.,
1994; Fernandes et al., 2012; Santos et al., 2013; Leão et al.,
2015). Briefly, the reserpine model recapitulates substantial
features of symptomatology, neurochemistry and pharmacology
of the disease (for a review see Leão et al., 2015). Recently,
we have proposed a repeated low-dose reserpine treatment
that produces progressive motor and non-motor symptoms
of PD, oxidative damage to membrane lipids, monoamine
depletion and reduction in tyrosine hydroxylase (TH) in the
nigrostriatal pathway (Fernandes et al., 2012; Santos et al.,
2013; Leão et al., 2015). In view of Abílio et al.’s (2004)
findings, which were focused on high-dose acute reserpine-
induced dyskinesia, we predict that SHR animals would also
be more resistant to repeated low-dose reserpine-induced
progressive motor impairment and cellular alterations. We
suggest that the comparison between SHR and Wistar rats
under this treatment could provide relevant information to
the understanding of susceptibility to factors involved in PD
etiology. Thus, we aimed to compare the development of
motor impairments and cellular hallmarks of PD (expression
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of TH and α-syn, and membrane lipid peroxidation) between
SHR and Wistar rats using the repeated low-dose reserpine
protocol.
MATERIALS AND METHODS
Animals
We used 7-month-old male Wistar and SHR rats. All animals
were housed in groups of 4–5 per cage (30 cm× 37 cm× 16 cm)
under conditions of acoustic isolation and controlled airflow
and temperature (23 ± 1◦C), with a 12 h light/12 h dark cycle
(lights on 6:30 a.m.). Food and water were available ad libitum.
Animals used in this study were handled in accordance with
the guidelines of the Brazilian law for the use of animals in
research (Law Number 11.794). All procedures were approved
by the local ethics committee (Comissao de Etica no uso de
animais da Universidade Federal do Rio Grande do Norte,
CEUA-UFRN #005/2014, and Comissao de Etica no uso de
animais da Universidade Federal de Sao Paul, CEUA-UNIFESP
#9239070815) and all efforts weremade tominimize animal pain,
suffering or discomfort.
Drugs and General Procedures
Reserpine (Sigma Chemical Co., St. Louis, MO, USA) was
dissolved in two drops of glacial acetic acid and diluted in
distilled water (0.1mg/ml). Vehicle consisted of the same amount
of acetic acid and water as in the reserpine solution. These
solutions were injected subcutaneously (s.c.). We briefly handled
animals for 2 min during 3 days before the beginning of the
experimental procedures.
Experimental Design
The rats from each strain (Wistar and SHR) were randomly
assigned to one of three groups: control (WIS-CTR: n = 8; SHR-
CTR: n = 10), reserpine-treated (WIS-RESt: n = 8; SHR-RESt:
n = 10) and reserpine-withdrawn (WIS-RESw/d: n = 8; SHR-
RESw/d: n = 10) groups. The animals received 15 s.c injections
of vehicle (CTR) or 0.1 mg/kg of reserpine (RESt and RESw/d)
at a volume of 1 ml/kg body weight, every other day. The rats
of the RESt group were euthanized 48 h after the 15th injection,
while CTR and RESw/d animals were euthanized 15 days after the
15th injection, for immunohistochemmical procedures. Motor
behavior data from RESt and RESw/d were considered together
for analysis until RESt group was euthanized (RES group).
Rats went through the following behavioral procedures (from
8:00 h to 16:00 h): (1) catalepsy test before the 1st injection
and every other day (8:00–9:00 h) throughout the treatment
and for 15 days after the last injection; (2) evaluation of
spontaneous activity in the open field after the 2nd, 6th and 15th
injections, and 15 days after withdraw (9:00–12:00 h); and (3) oral
movements quantification after the 2nd, 6th, 10th and 15th
injection, and 10 and 15 days after withdraw (13:00–16:00 h).
The behavioral tests listed were performed ∼48 h after the
referred injection, before the animals received the following
injection (16:00–17:00 h). Experimental design is shown in
Figure 1A.
Motor Behavior
Catalepsy Test
The catalepsy behavior was assessed by placing the animal’s
forepaws on a horizontal bar positioned at 9 cm above the
bench surface. Catalepsy was defined as an immobile posture,
keeping both forepaws on the bar. The duration of catalepsy was
measured up to a maximum of 180 s. Three trials were carried
out for each animal in each observation day and the mean value
of the three trials was considered for analysis.
Spontaneous Activity in the Open Field
The apparatus was a circular open field arena (84 cm in diameter)
with 32 cm high walls, made of wood and covered in black
laminated plastic. Animals were placed in the center of the
apparatus for free exploration during 5 min. A digital camera
above the apparatus recorded the sessions and an animal video-
tracking software (ANY-maze, Stoelting, Wood Dale, IL, USA)
registered the behavioral parameters. We quantified the distance
traveled (in meters) and the time moving above the speed of
0.05 m/s in the apparatus (in seconds).
Oral Movements
Rats were individually placed in a wired cage
(40 cm × 40.5 cm × 20 cm). Mirrors were positioned under the
floor and behind the back wall of the cage to allow behavioral
quantification when the animal faced away from the observer.
The number of tongue protrusions (projection of the tongue
out of the oral cavity) and the frequency of vacuous chewing
movements (mouth openings in the vertical plane not directed
toward physical material) were measured continuously for
10 min.
TH and α-syn Immunohistochemistry
Upon completion of the behavioral procedures, all animals
were anesthetized with an intraperitoneal injection of sodium
thiopental (40 mg/kg) and perfused transcardially with 200 ml
phosphate-buffered saline (PBS), pH 7.4, containing 500 IU
heparin (Liquemin, Roche, Brazil), followed by 300 ml 4.0%
paraformaldehyde in 0.1 M phosphate buffer, pH 7.4. The
brains were removed from the skull, postfixed in the same
fixative solution for 2–4 h, and transferred to a solution
containing sucrose 30% in 0.1 M PBS, pH 7.4. Each brain
was serially cut in the coronal plane into 50-µm thick
sections with a cryostat microtome (Leica, Germany) at a
temperature of −20◦C. The sections were placed sequentially
in five compartments (one section per compartment, 250-µm
apart) and stored in antifreeze solution. Free-floating sections
were incubated for 18–24 h with a polyclonal anti-TH (cat
# AB152 Chemicon, USA, 1:10,000, as described by Santos
et al. (2013) or anti-α-syn (cat # sc-7011-R, Santa Cruz Inc.,
Santa Cruz, CA, USA, 1:500) primary antibody raised in rabbit,
containing 2% goat normal serum diluted in 0.3% Triton
X-100 and 0.1 M phosphate buffer, pH 7.4. Sections were
incubated with the biotinylated secondary antibody anti-rabbit
(1:1000; cat # S-1000 Vector Labs, Burlingame, CA, USA)
obtained in goat for 2 h at room temperature, washed, and
incubated with avidin–biotin-peroxidase solution (ABC Elite
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FIGURE 1 | (A) Schematic representation of the experimental design. (B) Effects of repeated administration of 0.1 mg/kg reserpine on catalepsy behavior in Wistar
and spontaneously hypertensive rats (SHR) rats. Data are expressed as mean ± SEM relative to WIS-CTR group. ∗p < 0.05 comparing WIS-RES to WIS-CTR
(Two-way analysis of variance (ANOVA) with repeated measures followed by Sidak’s post hoc test).
kit, Vector Labs, Burlingame, CA, USA) for 90 min. The
reaction was developed by the addition of diaminobenzidine
tetrahydrochloride (Sigma, NY, USA) and 0.01% H2O2 in
0.1 M phosphate buffer, pH 7.4. The sections were washed
(4×, 5 min) with 0.1 M phosphate buffer, pH 7.4, between
each step and at the end of the procedure. Then, the sections
were dried, dehydrated in a graded alcohol series, cleared
in xylene, and cover slipped with Entellan (Merck). The
immunostainings were performed in four sessions with balanced
number of animals per group in each session, minimizing
possible differences in background between the groups due to
small variations in immunostaining. Sections were examined
under brightfield illumination (Olympus Microscope, BX-41),
images were captured using a CCD camera (Nikon, DXM-1200)
and the locations of areas were determined using the atlas of
Paxinos and Watson (2009).
Immunohistochemistry Quantification
In order to estimate the number of dopaminergic cells in
the SNpc four sections of each animal were selected: one at
the rostral level, two at the medium level and one at the
caudal level, representative of the rostrocaudal extension of
SNpc. The exact location of the region was determined on the
basis of the Paxinos and Watson rat brain atlas (2009; AP:
−5.04; −5.40; −5.52; −6.00 relative to the bregma). Briefly,
using an automated plate microscope (Olympus Microscope,
BX-41) and the software Stereo Investigator (MBF Bioscience,
Williston, VT, USA) we delineated the SNpc bilaterally in
the coronal sections previously described and sampled the
number of TH+ neuron bodies from 75 × 75 (µm) frames
into a 200 × 200 (µm) grid under a 100× oil immersion
objective. The TH+ cell count was performed for the whole
extension within each section. Number of neuron count was
then expressed relative to WIS-CTR group (Santos et al.,
2013).
Additionally, TH and α-syn levels were assessed by analysis
of relative optical densitometry (ROD) in the dorsal striatum
(dSTR; AP: 1.08; 0.36; 0.00; −0.72 relative to bregma) and
substantia nigra pars reticulada (SNpr, in the same coronal
sections as for the SNpc) using the software ImageJ (Version
1.46i, NIH). α-syn expresses in synaptic terminals, and a
previous study has shown immunoreaction for this protein
in the SNpr, co-localized with inhibitory terminals from the
dSTR. Of notice, that study did not show any protein inclusion,
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fibrils or neuron body staining in the SNpc (Taguchi et al.,
2016). The SNpr receives abundant afferences from striatal
medium spiny neurons and is one of the two output nuclei
from the basal ganglia to the motor thalamus, working as a
fast-spiking pacemaker in the absence of synaptic input (DeLong
and Wichmann, 2007; Da Cunha et al., 2009). Thus, the
quantification of α-syn expression in the SNpr may provide some
understanding on the status of the indirect pathway in the basal
ganglia.
Four representative sections of the rostrocaudal extension
of each region were chosen. In each section, five fields evenly
distributed throughout the areas of interest and control region
were analyzed. The medium pixels in the target area were
subtracted from the medium values of a control region (areas
that should not have specific TH staining) of the same tissue
(cortex or corpus calosum). Finally, all values were normalized
considering the Wistar control group, in order to evaluate
proportional alterations (Santos et al., 2013).
Lipid Peroxidation Assay
We performed an experiment to assess membrane lipid
peroxidation after reserpine treatment. We administered the
repeated-reserpine treatment protocol (15 s.c. injections of
0.1 mg/kg, every other day) to Wistar and SHR (WIS-CTR = 7;
WIS-RES = 7; SHR-CTR = 8; SHR-RES = 8). Forty-eight
hours after the last injection animals were euthanized by
decapitation, the brains were removed and the striatum were
dissected billateraly. The tissue was immediately weighed and
homogenized in phosphate buffer 0.1 M (1:5). Samples were
centrifuged for 15 min at 3500 rpm and 4–5◦C and duplicates
of the supernatant of each sample were used in the reaction.
Lipid peroxidation was estimated by the quantification of
malondialdehyde (MDA)—a fluorescent product formed from
the reaction of this aldehyde with thiobarbituric acid (TBA),
as described by Tanizawa et al. (1981). The reaction was
initiated by the addition of 250 µL of SDS 3%, 1.5 ml of acetic
acid buffer 2M, and 1.5 ml of TBA 0.8% to 50 µL of the
tissue homogenate. The volume was completed with 4 ml of
ultrapure water, incubated in a water bath at 95◦C for 60 min
and cooled in an ice-cold water bath. Finally, 2.5 ml from a
n-butanol:pyridine (15:1) mixture was added and samples were
vigorously agitated for 30 s. The results were expressed in
nanomoles (nm) of MDA per gram (g) of wet tissue calculated
by plotting the obtained fluorescence (excitation at 315 nm,
emission at 553 nm) against a standard MDA concentration
curve.
Data Analysis
Kolmogorov-Smirnov’s and Levene’s tests were used to analyze
normality of data and homogeneity of variance, respectively.
Parametric tests were used accordingly to data distribution
and homogeneity of variance. Two-way analysis of variance
(ANOVA) with repeated measures—with treatment and strain
as between-subject factors and sessions as within-subject
factor—were applied to catalepsy, open field and oral movement
motor parameters to assess effects throughout treatment
and withdraw phases. A two-way ANOVA was applied to
immunohistochemistry parameters with treatment and strain
as between-subject factors. Both tests were followed by Sidak’s
post hoc test to highlight differences between strain and treatment
groups. Results were expressed as mean + SEM and p< 0.05 was
considered to reflect significant differences. Exact p-values were
expressed for each factor and factor interactions for the two-way
ANOVA, while differences highlighted by the Sidak’s post hoc
test are assumed p< 0.05.
RESULTS
Motor Behavior
Catalepsy Test
Two-way ANOVA with repeated measures revealed effects
of session (F(15,750) = 3.187; p < 0.001), session∗strain
(F(15,750) = 2.766; p < 0.001), session∗treatment interaction
(F(15,750) = 3.162; p < 0.001), time∗treatment∗strain interaction
(F(15,750) = 1.950; p = 0.016) and treatment (F(1,50) = 4.151);
p = 0.047) during the treatment phase. The same analysis to the
withdraw phase did not reveal significant effects, and pointed
out only a marginal effect of time (F(6,192) = 2.120); p = 0.053).
Sidak’s post hoc test yielded differences only to WIS-RES group,
with animals spendingmore time in the bar than any other group
from 48 h after the 7th injection (day 17) to 48 h after the 15th
injection (day 31) of reserpine (Figure 1B). That is, the repeated
administration of reserpine resulted in the progressive increase
of latency to step down the bar only in the Wistar strain, and
this motor impairment was restored after treatment withdrawn
(Figure 1B).
Spontaneous Locomotion in the Open Field
Total distance traveled
Two-way ANOVA with repeated measures in the treatment
phase revealed effects of treatment (F(1,50) = 6.18; p = 0.016),
session (F(2,100) = 69.17; p < 0.001), session∗treatment
interaction (F(2,100) = 3.37; p = 0.038) and session∗strain
interaction (F(2,100) = 3.21; p = 0.044). Two-way ANOVA did
not found significant effects in the withdraw phase. Differences
between groups in each time point were yielded by Sidak’s
post hoc test and shown in Figure 2A. Only WIS-RES group
traveled a shorter distance relative to WIS-CTR group 48 h after
the 15th injection.
Speed above 0.05 m/s
Two-way ANOVA with repeated measures in the treatment
phase revealed effects of session (F(2,100) = 29.26; p < 0.001) and
session∗strain interaction (F(2,100) = 3.08; p = 0.050). Two-way
ANOVA did not found significant effects in the withdraw phase.
Differences between groups in each time point were yielded
by Sidak’s post hoc test and shown in Figure 2B. Briefly,
only WIS-RES group spent less time moving above 0.05 m/s
relative to WIS-CTR and SHR-RES groups 48 h after the 15th
injection.
Taken together, open field data indicate that the repeated
administration of reserpine resulted in the progressive
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FIGURE 2 | Effects of repeated administration of 0.1 mg/kg reserpine
on (A) total distance traveled and (B) time in speed above 0.05 m/s. Data are
expressed as mean ± SEM relative to WIS-CTR group. ∗p < 0.05 compared
to respective CTR group; #p < 0.05 compared to respective treatment in WIS
strain (Two-way ANOVA with repeated measures followed by Sidak’s post hoc
test).
impairment of spontaneous motor activity in both strains,
but with higher magnitude for the Wistar strain. Also, motor
impairment was restored after treatment withdrawn.
Oral Movements
Vacuous chewing
Two-way ANOVA with repeated measures in the treatment
phase revealed effects of session (F(3,150) = 13.81; p < 0.001),
treatment (F(1,50) = 23.33; p < 0.001), session∗strain interaction
(F(3,150) = 3.16; p = 0.026) and session∗treatment interaction
(F(3,150) = 11.33; p < 0.001). The same analysis revealed
effect of session (F(1,32) = 12.56; p < 0.001), treatment
(F(1,32) = 12.56; p = 0.001), session∗treatment∗strain interaction
(F(1,32) = 4.83; p = 0.035) and strain∗treatment interaction
(F(1,32) = 4.42; p = 0.043) in the withdraw phase. Differences
between groups in each time point were yielded by Sidak’s
post hoc test and shown in Figure 3A. WIS-RES presented
increase in the vacuous chewingmovements relative to respective
strain control from the 6th injection to 10 days after withdraw,
while SHR-RES presented increase in vacuous chewing only
after the 10th injection. As well, differences in the magnitude
of increase in vacuous chewing between reserpine-treated strains
occurred from the 10th injection to 15 days after withdraw, with
WIS-RES presenting higher values than SHR-RES group.
Tongue protrusion
Two-way ANOVA with repeated measures in the treatment
phase revealed effects of session (F(3,150) = 5.15; p < 0.05),
treatment (F(1,50) = 18.59; p < 0.001) and session∗treatment
interaction (F(3,150) = 5.94; p < 0.001). The same analysis
revealed effect of time (F(1,32) = 8.17; p < 0.05) and treatment
(F(1,32) = 8.48; p < 0.05) in the withdraw phase. Differences
between groups in each time point were yielded by Sidak’s
post hoc test and shown in Figure 3B. WIS-RES groups presented
increase in the tongue protrusion relative to WIS-CTR from
the 6th injection to 10 days after withdraw, while SHR-RES
(relative to SHR-CTR) presented increased values only after the
10th and 15th injections. No differences in the magnitude of
increase in tongue protrusion between reserpine-treated strains
was detected.
Overall, repeated reserpine treatment resulted in the
progressive increase in oral movements in both strains, but with
higher magnitude in the Wistar strain. Nevertheless, this effect
upon oral movements was restored after treatment withdrawn.
Neurochemistry
Tyrosine Hydroxylase
Two-way ANOVA for the number of TH positive neurons in
the SNpc revealed effects of treatment (F(2,54) = 3.39; p = 0.041)
and strain (F(1,54) = 7.44; p = 0.009; Figure 4A). Sidak’s post hoc
test revealed that WIS-RESw/d group presented reduction in
the number of TH+ neurons in the SNpc relative to WIS-CTR.
Moreover, SHR-RESt and SHR-RESw/d groups did not present
any differences in the TH+neuron count compared to SHR-CTR.
Further, SHR-RESw/d displayed increased TH+ neuron count in
the SNpc compared to WIS-RESw/d group. That is, only WIS
rats presented reductions in TH expression in the SNpc after
reserpine treatment.
Two-way ANOVA for TH expression in the dSTR revealed
only effects of treatment (F(2,54) = 7.61; p = 0.001), but a marginal
effect for strain (F(1,54) = 2.48; p = 0.068) was pointed out
(Figure 4B). Both WIS-RESt and SHR-RESt groups presented a
reduction in TH expression in the dSTR compared to respective
CTR groups. Despite this tendency, RESw/d groups did not differ
from CTR groups in any strain. Nevertheless, they did not differ
from RESt groups either. Differences between groups revealed by
Sidak’s post hoc test are shown in Figures 4A,B.
Overall, reserpine treatment resulted in a reduced
immunoreactivity to TH in the nigrostriatal pathway, but
SHR animals appeared to be more resistant to such decrease.
α-Synuclein
α-syn expression in the SNpc did not reveal any protein
inclusion, fibrils or neuron body staining. Two-way ANOVA
for α-syn expression in the SNpr revealed effects of treatment
(F(2,54) = 5.48; p = 0.007) and strain (F(1,54) = 4.27; p = 0.045).
Frontiers in Aging Neuroscience | www.frontiersin.org 6 March 2017 | Volume 9 | Article 78
Leão et al. SHR Resistant to Reserpine-Induced Parkinsonism
FIGURE 3 | Effects of repeated administration of 0.1 mg/kg reserpine on (A) vacuous chewing movements, and (B) tongue protrusions in oral movement test
in Wistar and SHR rats. Data are expressed as mean ± SEM. ∗p < 0.05 WIS-RES compared to WIS-CTR; @p < 0.05 SHR-RES compared to SHR-CTR; #p < 0.05
WIS-RES compared to SHR-RES (Two-way ANOVA with repeated measures followed by Sidak’s post hoc test).
Sidak’s post hoc test revealed that the SHR-RESt group presented
increased immunoreactivity to α-syn in the SNpr compared to
the SHR-RESw/d group (Figure 4C).
Two-way ANOVA for α-syn expression in the dSTR revealed
effects of treatment (F(2,54) = 5.39; p = 0.008) and strain
(F(1,54) = 9.59; p = 0.003). Both RESt groups presented an increase
in α-syn immunostaining compared to respective CTR and RESw
groups. Importantly, SHR-CTR and SHR-RESt group presented
a reduction of expression compared to respective treatment
groups in the WIS strain. Differences between groups revealed
by Sidak’s post hoc test and shown in Figure 4D.
Overall, reserpine treatment increased α-syn
immunostaining, and this effect was restored after withdraw. Of
notice, SHR strain displayed reduced α-syn expression regardless
of treatment.
Representative sections of each region analyzed for TH and
α-syn immunohistochemistry are presented in Figure 5.
Lipid Peroxidation Assay
Two-way ANOVA for MDA quantification revealed effects of
treatment (F(1,28) = 7.817; p = 0.01) and strain (F(1,28) = 28.536;
p< 0.001; Figure 6). Sidak’s post hoc test revealed that WIS-RES
group presented increased lipid peroxidation in the striatum
compared to WIS-CTR. Moreover, SHR-CTR and SHR-RES
groups presented decreased MDA concentration in the striatum
compared to the respective treatment group in Wistar strain.
Nonetheless, SHR-CTR and SHR-RES were not different from
each other (Figure 6). That is, SHR strain presented reduced
basal levels of MDA compared to Wistar, and reserpine-
treatment induced an increase in lipid peroxidation only in the
Wistar strain.
DISCUSSION
We found that SHR are resistant to catalepsy, spontaneous
locomotion and oral movement impairments in a reserpine-
induced progressive animal model of PD. As expected, reserpine-
treatedWistar rats presented a progressive increase in the latency
to step down the catalepsy bar, which was significant from the 8th
injection onwards (Figure 1B). Nevertheless, the SHR reserpine-
treated rats presented no increase in the latency to stepdown
whatsoever. Thus, the SHR strain was resistant to the difficulty to
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FIGURE 4 | Effects of repeated administration of 0.1 mg/kg reserpine on immunostaining for tyrosine hydroxylase (TH) in the (A) substantia nigra pars
compacta (SNpc) and (B) dorsal striatum (dSTR), and α-synuclein (α-syn) in the (C) SNpc and (D) dSTR in Wistar and SHR rats. Data are expressed as
mean ± SEM relative to WIS-CTR group. ∗p < 0.05 compared to respective CTR group; #p < 0.05 compared to respective treatment in WIS strain;
&p < 0.05 compared to respective RESt group; ••p < 0.05 effect of strain; @p < 0.05 effect of treatment (Two-way ANOVA followed by Sidak’s post hoc test).
start a movement induced by the low-dose reserpine treatment.
As follows, the same profile of motor impairment was evident
in the spontaneous locomotion in the open field. Despite both
strains significantly reduced locomotion and speed throughout
sessions due to habituation, only reserpine-treated Wistar rats
presented impaired spontaneous locomotion 48 h after the 15th
injection—to both total distance traveled and time in speed above
0.05 m/s (Figures 2A,B).
Despite the lower susceptibility to motor impairment in the
catalepsy and spontaneous locomotion test, reserpine-treated
SHR rats presented some extent of oral dyskinesia. However,
SHR-RES group presented an increase in oral movements
only after the 10th injection, which remained until the 10th
day of withdraw. Conversely, WIS-RES group displayed the
motor impairment after the 6th injection until the 15th day
of withdraw (Figures 3A,B). Moreover, the magnitude of
effects on oral movements was higher in Wistar rats than in
SHR rats. In summary, the motor profile of reserpine-treated
Wistar rats corroborates previous studies (Fernandes et al.,
2012; Santos et al., 2013). Importantly, the present results
show that the resistance to the acute high-dose reserpine-
induced oral dyskinesia that was previously reported (Queiroz
et al., 1998; Abílio et al., 2004) was extended to the low-dose
repeated regimen and to other motor parameters (catalepsy and
spontaneous activity) in the SHR strain.
Regarding the neurochemical analysis, we found a progressive
reduction in TH staining in the SNpc that was significant only
to WIS-RESw/d group, despite a tendency towards reduction
in WIS-RESt (p = 0.069; Figure 4A). Oppositely, the reserpine
treatment did not result in any reduction of TH staining in the
SNpc of SHR rats. On the other hand, both strains presented
a reduction in the TH staining after treatment with reserpine
in the dSTR, as well as a partial recovery relative to CTR and
RESt group in RESw/d groups (Figure 4B). The same profile of
recovery was reported for Wistar rats (10 injections of 0.1 mg/kg
every other day) by Santos et al. (2013) and Swiss mice (four
injections of 1 mg/kg every other day) by de Freitas et al.
(2016), which found partial recovery of immunoreactivity for
TH in the dSTR after 30 and 60 days of reserpine withdrawn,
respectively. These findings suggest a path of progression of
the reserpine-induced TH decrement from the fibers (dSTR) to
the nucleus (SNpc). Studies with other drug-induced models or
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FIGURE 5 | Representative photomicrographs of brain coronal sections of dSTR and substantia nigra of rats repeatedly treated with vehicle (CTR) or
0.1 mg/kg reserpine euthanized 48 h after last injection (RESt) or 15 days (RESw/d) after the last injection. Scale bar in dSTR: 1000 µm; and substantia
nigra: 200 µm.
FIGURE 6 | Effects of repeated administration of 0.1 mg/kg reserpine
on lipid peroxidation (malondyaldehyde—MDA formation) in the
striatum of Wistar and SHR rats. Data are expressed as mean ± SEM.
∗p < 0.05 compared to respective CTR group; #p < 0.05 compared to
respective treatment in WIS strain (Two-way ANOVA followed by Sidak’s
post hoc test).
parkinsonism also reported a retrograde profile of progression
(Zhu et al., 2004; Korecka et al., 2013). Importantly, this
trend of progression corroborates contemporary evidence that
during early PD progression the dopaminergic loss begins in
the projection sites, and subsequently advances to the nucleus
(Cheng et al., 2010).
Regarding the present results, the fact that the TH decrement
was found in the dSTR but not in the SNpc of SHR reinforces
the notion that the dopaminergic loss did not progress in this
strain in the same magnitude as it did in Wistar animals.
Indeed, the reduction in TH staining in the dSTR of SHR
strain was not enough to cause expressive motor impairments.
Thus, it is likely that the impairing effects on motor activity of
reserpine treatment requires the decrement of TH in the SNpc,
which occurred only in the Wistar strain (Figures 4A,B). That
is in accordance with the motor progression of PD, because
the motor impairments in patients are observed only after the
loss of at least a quarter of neurons in the SNpc (Arkadir
et al., 2014). Nevertheless, WIS-RESw/d group, despite reduced
TH+ neuron count in the SNpc, presented recovery of motor
impairment (Figure 4A). Thus, other adaptive mechanisms
could be related to this finding. As far as the SHR strain
is concerned, other neurochemical alterations—than the TH
expression—could have precluded the motor deficit induced
by reserpine repeated treatment. Recently, we have found that
the magnitude of motor deficit corresponded to the extent
of dopamine depletion in Wistar compared to SHR animals
(unpublished data).
In this respect, such neurochemical findings could be
secondary to alterations in catecholamine levels and metabolism
imbalances. Indeed, catecholamines regulate TH activity and
expression in the cytoplasm (Dickson and Briggs, 2013). Thus,
the resulting increase of DA in the cytoplasm by reserpine
treatment may reduce the TH activity in the nigrostriatal
pathway. Alternatively, NO and nitrite formation in the
cytoplasm also regulates the expression of TH (Daubner et al.,
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2011; Nakashima et al., 2011). In this respect, reserpine
treatment results in oxidative stress and accumulation of
reactive oxygen and nitrogen specimens, which ultimately
may result in the decrement of TH expression (Arora et al.,
2011; Arora and Chopra, 2013; Santos et al., 2013). Here
we report reduced lipid peroxidation (evaluated by MDA
formation) in SHR relative to Wistar rats. Further, reserpine
treatment resulted in increased MDA formation only in the
Wistar strain (Figure 6), corroborating findings by Abílio
et al. (2004) and Fernandes et al. (2012). That is, SHR rats
have a reduced baseline for the formation of oxidative stress
products, which ultimately may confer resistance to reserpine-
induced oxidative stress. In fact, Abílio et al. (2004) have
associated such resistance to increased activity of catalase in
the SHR strain. Further investigations of which phosphorylated
site of TH is involved in the regulation of TH expression in
response to the treatment with reserpine is required to clarify
the mechanisms of TH downregulation. Likewise, epigenetic
studies could also help to clarify how such cellular oxidative
imbalance would modulate the expression of TH (Yang et al.,
2011).
From another standpoint, the present results also showed
strain differences in α-syn expression. Specifically, both
RES-treated groups presented an increase in the expression of
α-syn relative to CTR and RESw/d groups (particularly in the
dSTR, Figures 4C,D). However, SHR rats presented a reduction
of α-syn expression relative to WIS rats in both SNpc and
dSTR (Figures 4C,D), irrespective of treatment. This findings
corroborate the study of Chiavegatto et al. (2009) that report
reduced expression of α-syn in the hippocampus of SHR rats
compared to the Lewis strain.
Thus, the reported reduced expression of α-syn in this
strain may reflect a significant relevance to the resistance
to motor impairments showed by SHR animals. It is well
known that the stable form of α-syn is localized in membranes
and vesicles of presynaptic terminals in a stable membrane-
bound state (Burré, 2015). The stable form is in dynamic
equilibrium with the soluble cytosolic α-syn, a monomeric
and natively unfolded protein that can be converted into
β-sheet containing oligomers (protofibrils), which eventually
form amyloid-like fibrils and Lewy bodies (Burré et al., 2013).
Thus, an increase in the soluble cytosolic form of α-syn is
detrimental to catecholaminergic neurons because there is an
increased probability of formation of β-sheet and protofibrils.
Nevertheless, despite the increase in α-syn immunostaining, we
did not detect any protein inclusions or fibrils formation with
the length of repeated reserpine treatment used here (Figure 5).
Even so, the reduced α-syn expression in SHR compared to
Wistar strain (Figures 4C,D) denotes a mechanism by which
reserpine-treated SHR rats may cope with DA imbalances and
TH downregulation.
Indeed, α-syn is involved in the homeostasis of DA by
inhibiting the expression and activity of TH and VMAT2
(Baptista et al., 2003; Guo et al., 2008), and interrupting
dopamine balance by causing increased cytosolic dopamine
levels (Perez et al., 2002). Conversely, catecholamine metabolites,
such as 5-S-Cysteinyldopamine, modulate α-syn expression
through oxidative stress (Aureli et al., 2014). Thus, reserpine-
induced increases in catecholamine metabolites and oxidative
imbalances may be in the core of the neurochemical alterations
reported here (Leão et al., 2015). Accordingly, SHR rats,
which show decreased imunostainning for α-syn (Figure 4D),
also presented reduced levels of lipid peroxidation (Figure 6).
Therefore, SHR rats appear to be better suited to cope
with oxidative imbalances resulting from reserpine treatment,
and this feature could be related to the different profiles
of TH and α-syn expressions between Wistar and SHR
strains.
Of notice, irrespective of strains differences, this is the first
study to show increased expression of α-syn in reserpine-
treated mammals. To our knowledge, only one previous study
investigated the effects of reserpine on α-syn expression in a
Droshophila melanogaster model. That study reported inhibition
of the autophagic flux, disruption in protein degradation, and
accumulation of α-syn-rich protein aggregates (Lee et al., 2015).
Accordingly, VMAT2-deficient mice presented age-dependent
neurodegeneration in the SNpc, followed by α-syn accumulation
and TH immunostaining reduction (Caudle et al., 2007;
Taylor et al., 2009). Despite overall motor and neurochemical
results pointing towards a reversible reserpine-induced insult
to the nigrostriatal pathway (present results; Fernandes et al.,
2012; Santos et al., 2013), we do not discard some extent
of neurodegeneration and α-syn rich protein inclusions or
fibrils in longer treatment regimens. As follows, long-term
VMAT2 blockade or loss of function results in irreversible
neurochemical and behavioral alterations (Neisewander et al.,
1991), as well as neurodegeneration (Taylor et al., 2011). Thus,
investigation of neurodegenerative markers and defective protein
accumulation are still required to clarify this matter. For instance,
reserpine treatment results in increased expression of caspase-3
(Arora and Chopra, 2013; Liu et al., 2014) and reduction of
Bcl-2 (Liu et al., 2014; El-Ghazaly et al., 2015), which are
important markers of apoptotic pathways commitment. Finally,
the increase in the α-syn found in reserpine-treated animals is a
putative secondary mechanism by which TH is downregulated.
Indeed, α-syn reduces TH expression through inhibition of
phosphorylation at Ser40 of TH (Peng et al., 2005; Wu et al.,
2011).
In summary, even though we do not report any sign of
α-syn positive protein inclusions, we suggest that the behavioral
and neurochemical alterations here reported resembles a closer
relationship to early PD molecular alterations. Nonetheless,
other chemically induced PD models do not account for
this histopathological hallmark (Meredith et al., 2008; Blesa
et al., 2012). Importantly, the differences between the two
strains could shed light on these initial cellular alterations.
That is, the different profiles described here may result from
compensatory and/or plastic mechanisms related to the reduced
α-syn expression, resistance to the TH decrement in the
SNpc, and reduced oxidative damage exhibited by the SHR
strain.
In view of such findings, it is clear that the interaction between
the genetic background of rat strains (genetic factors) and
neurotoxic treatments (environmental factors) is substantial to
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the expression of motor and cellular alterations in the progressive
PD model induced by repeated reserpine treatment. Beyond
the aforementioned evidence, SHR rats present other cellular
features of the dopaminergic system that are relevant to the
understanding of PD. For example, SHR rats express more
D1 and DAT in the striatum (Watanabe et al., 1997), but present
reduced function of the latter (Russell, 2003). They also seem to
express less TH in the pre-frontal cortex (King et al., 2000) among
other neurochemical alterations (for a review see Viggiano et al.,
2004). Ideally, the investigation of the SHR strain neurochemical
differences in the catecholaminergic system should be extended
to other parameters and rat strains.
In conclusion, here we demonstrate that SHR rats are resistant
to a progressive reserpine-induced PD model. In the Wistar
strain, the motor impairments were followed by compatible
neurochemical alterations that reflected PD progression,
namely reduced TH and increased α-syn expressions in the
substantia nigra and dSTR. On the other hand, motor and
neurochemical data from the SHR strain revealed a dissociation
of neurochemical alterations and motor behavior—for example,
reduced TH expression in the dSTR, but no motor impairment.
Here we highlight some of the neurochemical differences
between these strains that may be adaptive to PD resistance, such
as reduced expression of α-syn and oxidative stress products
in the SHR strain. Nevertheless, the underlying mechanism
by which such resistance is granted to SHR rats remains to
be investigated. In view of these findings, we suggest the SHR
resistant strain and the repeated low-dose reserpine protocol
as valuable animal resources to investigate the relevance of
genetic, cellular and behavioral features to the of progression
of PD.
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